Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eVOLVE-Meso: Volrustomig + Carboplatin + Pemetrexed vs Standard Regimens in Unresectable Pleural Mesothelioma
2023-503231-17-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Dec 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of volrustomig in pleural mesothelioma (3 arms), sponsored by AstraZeneca. Primary endpoint: Overall survival. Planned start Dec 2023; status: authorised.
02
Drugs
volrustomig
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2023-503231-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503231-17-00.